MedPage Today on MSN
Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer
POTOMAC data support a year's worth of immuontherapy paired with BCG induction and mainten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results